<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03107871</url>
  </required_header>
  <id_info>
    <org_study_id>90760</org_study_id>
    <nct_id>NCT03107871</nct_id>
  </id_info>
  <brief_title>Randomized Controlled Trial of Valganciclovir for Asymptomatic Cytomegalovirus Infected Hearing Impaired Infants</brief_title>
  <acronym>ValEAR</acronym>
  <official_title>Randomized Controlled Trial of Valganciclovir for Asymptomatic Cytomegalovirus Infected Hearing Impaired Infants: ValEAR Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albert Park</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Deafness and Other Communication Disorders (NIDCD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goal of this study is to determine the clinical benefit and safety of antiviral
      therapy for asymptomatic congenital cytomegalovirus (cCMV) infected hearing-impaired infants.
      We will conduct a multi-center double-blind randomized placebo-controlled trial to determine
      whether hearing-impaired infants with asymptomatic cCMV have better hearing and language
      outcomes if they receive valganciclovir antiviral treatment. We will also determine the
      safety of antiviral valganciclovir therapy for asymptomatic cCMV-infected hearing impaired
      infants. This study will be unique in that the cohort enrolled will only include
      hearing-impaired infants with asymptomatic cCMV.

      Aim 1: Test the hypothesis that asymptomatic CMV-infected hearing impaired infants treated
      with antiviral valganciclovir will have better hearing and language outcomes compared with
      untreated CMV-infected hearing impaired infants.

      Aim 2: Evaluate the safety of antiviral valganciclovir therapy for asymptomatic CMV-infected
      hearing impaired infants.

      Aim 3: Evaluate the pharmacokinetics (pK) of valganciclovir using pharmacometrics modeling to
      develop a population pK model.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cytomegalovirus (CMV) can be transmitted from the mother to the fetus and is a leading cause
      of sensorineural hearing loss (SNHL), which is a condition where the inner ear is unable to
      convert sound into nerve impulses to the brain. This hearing loss and its detrimental effect
      on language development contribute nearly $4 billion annually to the health care costs in the
      U.S. Unlike other types of SNHL, CMV induced hearing loss can be treated. Several clinical
      trials have demonstrated that antiviral therapy may prevent progressive hearing loss if
      administered early in life for severely affected (symptomatic CMV) infants. These promising
      findings have given rise to a debate regarding the best method for identifying and treating
      the more numerous asymptomatic CMV-infected infants.

      One approach is to conduct universal newborn hearing screens, and then do CMV diagnostic
      testing only on the infants who fail the hearing screen. This targeted approach should
      identify those infants at greatest risk of developing progressive hearing loss and consequent
      communicative difficulties. Utah is the first state to mandate this approach whereby infants
      under three weeks of age who fail their newborn hearing screening undergo CMV testing. In
      this trial, the hearing screen targeted approach will be used to identify patients eligible
      for participation in a double blind placebo controlled randomized clinical trial of antiviral
      valganciclovir therapy. The results of this trial will inform public policy, potentially
      shift our current clinical practice regarding pediatric hearing loss evaluation, and
      potentially offer a therapeutic option to asymptomatic CMV-infected infants with SNHL.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2017</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Placebo and active drug will be dispensed in identical amber bottles with identical labeling.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Best-Ear Hearing Score</measure>
    <time_frame>Assessed at 12 months of age</time_frame>
    <description>The primary outcome is defined as the change from baseline to age 12 months in the best-ear hearing score in the hearing score corresponding to the best ear at each time point.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Substantial Best-Ear Worsening Hearing Composite Outcome</measure>
    <time_frame>Assessed at 12 and 24 months of age</time_frame>
    <description>A clinically significant worsening hearing in the best ear will be defined as the occurrence of a) Cochlear implantation or b) a 20 decibel (dB) or greater increase in the best ear minimum response level (MRL) for at least one of the frequencies 1 kilohertz (kHz), 2 kHz, or 4 kHz but no decrease in the best ear MRL at any of these three frequencies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Communicative Development Outcome</measure>
    <time_frame>Assessed at 12 and 24 months of age</time_frame>
    <description>Communicative development outcome is the MacArthur-Bates Communicative Development Inventory (CDI) summary score. The summary score is defined by averaging the percentile scores of the four domains of this instrument.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Cmv Congenital</condition>
  <condition>CMV</condition>
  <condition>Congenital Cmv</condition>
  <condition>SNHL</condition>
  <condition>Sensorineural Hearing Loss</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Valganciclovir 16 mg/kg PO twice daily (BID) x 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Flavored Simple Syrup, volume equivalent to active arm dose, PO BID x 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valganciclovir</intervention_name>
    <description>Valganciclovir is supplied as a powder for reconstitution into an oral solution. The reconstituted solution formulation comprises the following excipients: Povidone K30, fumaric acid, sodium benzoate, saccharin sodium, mannitol, flavor, and purified water.</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>Valcyte</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simple Syrup</intervention_name>
    <description>Simple Syrup contains sucrose 85% weight by volume, purified water, and methyl paraben as a preservative along with natural preservatives. It will be flavored to match the flavor of valganciclovir.</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age less than 6 months at the time of randomization; AND

          -  Less than or equal to 37 weeks gestational age at birth; AND

          -  Positive congenital CMV by urine culture or polymerase chain reaction test(PCR), OR
             saliva culture or PCR followed by confirmatory urine PCR by 21 days of age, OR urine
             culture or PCR after 21 days of age followed by newborn dry blood spot PCR; AND

          -  Failed hearing screen, with confirmed sensorineural hearing loss (SNHL) by auditory
             brainstem response (ABR) testing.

        Exclusion Criteria:

          -  Imminent demise; OR

          -  Lack of commitment to aggressive care; OR

          -  Significant gastrointestinal disorders (e.g., eosinophilic esophagitis, ulcerative
             colitis); OR

          -  Significant hematologic disorders (e.g., hemophilia, leukemia, sickle cell anemia); OR

          -  Significant renal disorders (e.g., nephrotic syndrome); OR

          -  Receiving other antiviral medications or immune globulin therapy; OR

          -  Receiving other investigational drugs; OR

          -  Breast feeding from a mother receiving antiviral or immunosuppressive medication; OR

          -  Other known cause contributing to SNHL (e.g., meningitis, aminoglycoside ototoxicity);
             OR

          -  Bilateral profound SNHL or auditory neuropathy spectrum disorder; OR

          -  Evidence of intracranial calcification; OR

          -  Evidence of hydrocephalus; OR

          -  Microcephaly; OR

          -  Presence of petechiae; OR

          -  Intrauterine growth retardation; OR

          -  Hepatitis; OR

          -  Parent or guardian unable to speak English or Spanish; OR

          -  Patient unable to attend follow-up hearing and developmental assessment at 12 months
             of age.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>5 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albert Park, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephanie Bisping, BSN</last_name>
    <phone>801-587-7758</phone>
    <email>stephanie.bisping@hsc.utah.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kaitlin Cooley</last_name>
    <phone>801-213-4055</phone>
    <email>kaitlin.cooley@hsc.utah.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Arkansas Children's Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chuck Bower, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lucile Packard Children's Hospital</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alan Cheng, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rady Children's Hospital - San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniela Carvalho, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCSF Benioff Children's Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dylan Chan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connecticut Children's Medical Center</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Scott Schoem, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yale New Haven Children's Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eugene Shapiro, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Christiana Hospital</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carlos Duran, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kavita Dedhia, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lurie Children's Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephen Hoff, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medicine Comer Children's Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Allison Bartlett, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NorthShore University Healthsystem</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mark Gerber, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>George Harris, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Indiana University School of Medicine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>John Dahl, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts Eye and Ear</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Cohen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Masonic Children's Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mark Schleiss, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's of Mississippi</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jeff Carron, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pamela Nicklaus, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eli Grunstein, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cohen Children's Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sunil Sood, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Doernbecher Children's Hospital</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carol MacArthur, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>John Germiller, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Chi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Monroe Carell Jr. Children's Hospital at Vanderbilt</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frank Virgin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Angela Shoup, Ph.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gail Harrison, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Health</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ken Lee, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Primary Children's Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Albert Park, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of The King's Daughters</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephanie Antonio, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>British Columbia Children's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 3N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2017</study_first_submitted>
  <study_first_submitted_qc>April 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2017</study_first_posted>
  <last_update_submitted>September 26, 2017</last_update_submitted>
  <last_update_submitted_qc>September 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>Albert Park</investigator_full_name>
    <investigator_title>Chief Peds Otolaryngology</investigator_title>
  </responsible_party>
  <keyword>valganciclovir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hearing Loss</mesh_term>
    <mesh_term>Hearing Loss, Sensorineural</mesh_term>
    <mesh_term>Deafness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valganciclovir</mesh_term>
    <mesh_term>Ganciclovir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

